Precision Therapeutics Inc., a firm that applies artificial intelligence (AI) to both drug discovery and personalized medicine, recently revealed that it had secured the rights to a new technology, specifically designed for the proprietary culture media to develop ovarian cancer cell types for testing and research in the lab.
GLG Pharma LLC, a joint venture partner of Precision Therapeutics, has accepted the non-exclusive license terms to this novel technology drawn from a research institution.
TumorGenesis, Inc., a Precision fully-owned subsidiary, has come up with a discovery kit by utilizing this technology, which is designed to screen these ovarian cancer cell types.
This effort forms part of the collaboration between GLG and TumorGenesis to boost ovarian cell culture, chemistry, and capture.
14 out of the 24 recognized ovarian cancer cell types make up 90% all the ovarian cancers, the first drug discovery target for TumorGenesis.
The creation of this kit marks the first milestone in the firm ’s endeavor to develop human tumors, especially outside the body.
The other three milestones include spotting the structure and peptides for growing a tumor, choosing the one that works appropriately, and then exogenously growing a tumor.
Precision Therapeutics’ Chief Operating Officer and Member of the Board Richard Gabriel said: “The first discovery kit has been built and is being made available to clients of TumorGenesis for whole cell screening in Clinical Research Projects. We believe this screening will represent a major breakthrough for ovarian cancer patients, as these cells are unique and are difficult to culture. With TumorGenesis biomarkers for ovarian cancer, upon completion of the next milestones, researchers will be able to fool ovarian cancer cells into growing as if they were still in the patient. This will help our pharmaceutical clients research and develop new drugs or a combination therapy with previously approved drugs to improve patient outcomes.”
GLG Pharma’s Chief Executive Officer, Ph.D., and MD Hector J. Gomez stated: “In ovarian cancer, fewer than 40% of the women survive from the standard of care treatment that is usually Taxol combined with Cisplatin or Carboplatin. The odds are basically a 50-50-coin toss. Our joint venture’s approach, which targets cancer by the patient’s specific mutation, is designed to change the paradigm from a 50-50 to a 70-30 or higher ratio in favor of the patient.”
Dr. Carl Schwartz, the chief executive officer of Precision Therapeutics, said: “The licensing of the growth media by our partner, GLG, is crucial to growing reliable ovarian cancer cells that are more closely matched to the patient’s cancer cells. TumorGenesis is targeting the Clinical Research market, and GLG is targeting clinical trials and FDA compliance in combination with their own drugs. We are extremely pleased with our partnership and advancement to help women who are subjected to this insidious and lethal disease.”